Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Alnylam Pharmaceuticals Inc’s stock clocked out at $250.00, down -2.52% from its previous closing price of $256.45. In other words, the price has decreased by -$2.52 from its previous closing price. On the day, 0.91 million shares were traded.
Ratios:
To gain a deeper understanding of ALNY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.78. In the meantime, Its Debt-to-Equity ratio is 40.89 whereas as Long-Term Debt/Eq ratio is at 38.58.
Goldman Upgraded its Neutral to Buy on August 16, 2024, whereas the target price for the stock was revised from $198 to $370.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 14 ’25 when Greenstreet Yvonne sold 1,213 shares for $255.17 per share. The transaction valued at 309,527 led to the insider holds 81,526 shares of the business.
Poulton Jeffrey V. sold 967 shares of ALNY for $246,750 on Feb 14 ’25. The EVP, Chief Financial Officer now owns 32,786 shares after completing the transaction at $255.17 per share. On Feb 18 ’25, another insider, Fitzgerald Kevin Joseph, who serves as the CSO & EVP, Head of Research of the company, sold 1,440 shares for $251.56 each. As a result, the insider received 362,243 and left with 12,881 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 14.40 while its Price-to-Book (P/B) ratio in mrq is 481.81.
Stock Price History:
Over the past 52 weeks, ALNY has reached a high of $304.39, while it has fallen to a 52-week low of $141.98. The 50-Day Moving Average of the stock is -1.95%, while the 200-Day Moving Average is calculated to be 3.62%.
Shares Statistics:
A total of 129.29M shares are outstanding, with a floating share count of 123.76M. Insiders hold about 4.40% of the company’s shares, while institutions hold 95.36% stake in the company.
Earnings Estimates
The current rating of Alnylam Pharmaceuticals Inc (ALNY) reflects the combined expertise of 9.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.25, with high estimates of $0.43 and low estimates of -$0.74.
Analysts are recommending an EPS of between $1.81 and -$1.06 for the fiscal current year, implying an average EPS of $0.59. EPS for the following year is $3.38, with 15.0 analysts recommending between $11.09 and $0.27.
Revenue Estimates
In the current quarter, 17 analysts expect revenue to total $593.56M. It ranges from a high estimate of $667.5M to a low estimate of $532M. As of the current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $494.33MFor the next quarter, 17 analysts are estimating revenue of $644.03M. There is a high estimate of $766.3M for the next quarter, whereas the lowest estimate is $580M.
A total of 27 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $3.07B, while the lowest revenue estimate was $2.48B, resulting in an average revenue estimate of $2.84B. In the same quarter a year ago, actual revenue was $2.25BBased on 28 analysts’ estimates, the company’s revenue will be $3.55B in the next fiscal year. The high estimate is $4.56B and the low estimate is $3.1B.
